Evaluating the efficacy of stem cells in treating severe dry eye disease

doi:10.4252/wjsc.v17.i4.101891

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (299)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

169

Figures (1-1)

Tables (1-3)

Sum=214

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=63

Publishing Process of This Article

Item

Count

Browse

Download

Sum=15

Apr 26, 2025 (publication date) through Apr 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Apr 26, 2025; 17(4): 101891
Published online Apr 26, 2025. doi: 10.4252/wjsc.v17.i4.101891

Table 2 Comparison of different stem cell sources in dry eye disease treatment

Stem cell source	Differentiation potential	Anti-inflammatory properties	Clinical applications	Key findings
AD-MSCs[74,76,84]	Multipotent	High secretion of anti-inflammatory cytokines	Used in limbal stem cell deficiency and corneal wound healing	Show promising anti-inflammatory and regenerative effects
BM-MSCs[36,85,86]	Multipotent	Moderate secretion of anti-inflammatory cytokines	Used in severe DED and Sjögren’s syndrome-related dry eye	Effective in reducing inflammation and promoting epithelial proliferation
UC-MSCs[75,86-90]	Higher plasticity than AD-MSCs and BM-MSCs	High immunomodulatory potential	Investigated for corneal and lacrimal gland regeneration	Exhibits low immunogenicity and enhances corneal healing

AD-MSCs: Adipose-derived mesenchymal stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem cells; UC-MSCs: Umbilical cord-derived mesenchymal stem cells; DED: Dry eye disease.

Citation: Fu L, Pelosini L, Kopsachilis N, Foti R, D’Esposito F, Musa M, D’Amico A, Tognetto D, Gagliano C, Zeppieri M. Evaluating the efficacy of stem cells in treating severe dry eye disease. World J Stem Cells 2025; 17(4): 101891
URL: https://www.wjgnet.com/1948-0210/full/v17/i4/101891.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i4.101891